PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-31.28%
Both yoy net incomes decline, with RVPH at -18.94%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
1.30%
D&A growth of 1.30% while RVPH is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
No Data
No Data available this quarter, please select a different quarter.
41.15%
SBC growth of 41.15% while RVPH is zero at 0.00%. Bruce Berkowitz would see some additional share issuance that must be justified by expansions or retention needs.
170.16%
Slight usage while RVPH is negative at -100.00%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
170.16%
Growth well above RVPH's 100.00%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
169.42%
Well above RVPH's 28.27%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
-4.39%
Negative yoy CFO while RVPH is 796.90%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
94.15%
CapEx growth of 94.15% while RVPH is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
We expand invests by 100.00% while RVPH is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
No Data
No Data available this quarter, please select a different quarter.
-97.06%
Negative yoy issuance while RVPH is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.